Pharmacology-Based Prediction of the Targets and Mechanisms for Icariin against Myocardial Infarction

Background and Objectives: This study aims to illustrate the mechanisms underlying the therapeutic effect of Icariin after myocardial infarction (MI). Materials and Methods: Based on the network pharmacology strategy, we predict the therapeutic targets of Icariin against MI and investigate the pharmacological molecular mechanisms. A topological network was created. Biological process and Kyoto Encyclopedia of Genes and Genomes pathway enrichment were also performed. We also conducted the molecular docking analysis to stimulate the component–target interaction further and validate the direct bind effect. Results: Network pharmacology analysis identified 61 candidate genes related to the therapeutic effect of Icariin against MI. EGFR, AKT1, TP53, JUN, ESR1, PTGS2, TNF, RELA, HSP90AA1, and BCL2L1 were identified as hub genes. The biological processes of the candidate targets were significantly involved in the reactive oxygen species metabolic process, response to hypoxia, response to decreased oxygen levels, response to oxidative stress, regulation of reactive oxygen species metabolic process, and so forth. Overall, biological process enrichment analysis indicated that the protective effect of Icariin against MI might be associated with oxidative stress. Moreover, the pathway analysis showed that the candidate targets were closely associated with lipid and atherosclerosis, AGE-RAGE signaling pathway in diabetic complications, HIF-1 signaling pathway, etc. We identified the conformation with the lowest affinity score as the docking conformation. The simulated molecular docking was displayed to illustrate the topical details of the binding sites between Icariin and TNF protein. Conclusions: This study provides an overview of the mechanisms underlying the protective effect of Icariin against MI.

[1]  Yufeng Shi,et al.  An Epigenetic Role of Mitochondria in Cancer , 2022, Cells.

[2]  Wei Zhang,et al.  Anti-inflammatory and immunoregulatory effects of icariin and icaritin. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  W. Liu,et al.  Icariin exhibits protective effects on cisplatin-induced cardiotoxicity via ROS-mediated oxidative stress injury in vivo and in vitro. , 2022, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[4]  K. Chen,et al.  Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers , 2022, Frontiers in Oncology.

[5]  U. Ashfaq,et al.  Network Pharmacology Approach for Medicinal Plants: Review and Assessment , 2022, Pharmaceuticals.

[6]  I. Akushevich,et al.  Epidemiology of Geographic Disparities of Myocardial Infarction Among Older Adults in the United States: Analysis of 2000–2017 Medicare Data , 2021, Frontiers in Cardiovascular Medicine.

[7]  Feng Dong,et al.  Icariin inhibits hypoxia/reoxygenation‐induced ferroptosis of cardiomyocytes via regulation of the Nrf2/HO‐1 signaling pathway , 2021, FEBS open bio.

[8]  R. Roman,et al.  Novel Mechanistic Insights and Potential Therapeutic Impact of TRPC6 in Neurovascular Coupling and Ischemic Stroke , 2021, International journal of molecular sciences.

[9]  S. Madhunapantula,et al.  Mitochondrial mutations and mitoepigenetics: focus on regulation of oxidative stress-induced responses in breast cancers. , 2020, Seminars in cancer biology.

[10]  Hui Zhang,et al.  A network pharmacology approach to investigating the mechanism of Tanshinone IIA for the treatment of liver fibrosis. , 2020, Journal of ethnopharmacology.

[11]  M. Gulati,et al.  Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions , 2020, Current Atherosclerosis Reports.

[12]  S. Sharma,et al.  Icariin attenuates isoproterenol-induced cardiac toxicity in Wistar rats via modulating cGMP level and NF-κB signaling cascade , 2019, Human & experimental toxicology.

[13]  Feng Zhu,et al.  Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics , 2019, Nucleic Acids Res..

[14]  F. Sanz,et al.  The DisGeNET knowledge platform for disease genomics: 2019 update , 2019, Nucleic Acids Res..

[15]  Meide Zhang,et al.  Network pharmacology‐based research on the active component and mechanism of the antihepatoma effect of Rubia cordifolia L. , 2019, Journal of cellular biochemistry.

[16]  Olivier Michielin,et al.  SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules , 2019, Nucleic Acids Res..

[17]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association , 2019, Circulation.

[18]  Chao Huang,et al.  An outline for the pharmacological effect of icariin in the nervous system , 2019, European journal of pharmacology.

[19]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[20]  The UniProt Consortium,et al.  UniProt: a worldwide hub of protein knowledge , 2018, Nucleic Acids Res..

[21]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2019 , 2018, Nucleic Acids Res..

[22]  S. Di,et al.  Icariin protects cardiomyocytes against ischaemia/reperfusion injury by attenuating sirtuin 1‐dependent mitochondrial oxidative damage , 2018, British journal of pharmacology.

[23]  B. Mi,et al.  Icariin Activates Autophagy via Down-Regulation of the NF-κB Signaling-Mediated Apoptosis in Chondrocytes , 2018, Front. Pharmacol..

[24]  Shunan Ye,et al.  Icariin promotes wound healing by enhancing the migration and proliferation of keratinocytes via the AKT and ERK signaling pathway , 2018, International journal of molecular medicine.

[25]  Weimin Wang,et al.  Icariin influences cardiac remodeling following myocardial infarction by regulating the CD147/MMP-9 pathway , 2018, The Journal of international medical research.

[26]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association , 2018, Circulation.

[27]  Z. Wang,et al.  The effect of icariin on bone metabolism and its potential clinical application , 2018, Osteoporosis International.

[28]  Yongjun Zhang,et al.  Icariin, an Anti-atherosclerotic Drug from Chinese Medicinal Herb Horny Goat Weed , 2017, Front. Pharmacol..

[29]  Meng-Ling Wu,et al.  Icariin attenuated oxidative stress induced-cardiac apoptosis by mitochondria protection and ERK activation. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[30]  Kok-Gan Chan,et al.  Anti-Cancer Properties of the Naturally Occurring Aphrodisiacs: Icariin and Its Derivatives , 2016, Front. Pharmacol..

[31]  Shuliang Song,et al.  Icariin inhibits atherosclerosis progress in Apoe null mice by downregulating CX3CR1 in macrophage. , 2016, Biochemical and biophysical research communications.

[32]  Bo Sun,et al.  Icariin Attenuates High-cholesterol Diet Induced Atherosclerosis in Rats by Inhibition of Inflammatory Response and p38 MAPK Signaling Pathway , 2016, Inflammation.

[33]  Damian Szklarczyk,et al.  STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data , 2015, Nucleic Acids Res..

[34]  Hong-Bo Xiao,et al.  Icariin regulates PRMT/ADMA/DDAH pathway to improve endothelial function , 2015, Pharmacological reports : PR.

[35]  T. Aittokallio,et al.  Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. , 2015, Natural product reports.

[36]  Jia-Yi Li,et al.  Tumor necrosis factor-α and its role as a mediator in myocardial infarction: A brief review , 2015, Chronic diseases and translational medicine.

[37]  Hongmei Zhao,et al.  Icariin Acts as a Potential Agent for Preventing Cardiac Ischemia/Reperfusion Injury , 2015, Cell Biochemistry and Biophysics.

[38]  H. Fang,et al.  Icariin Intervenes in Cardiac Inflammaging through Upregulation of SIRT6 Enzyme Activity and Inhibition of the NF-Kappa B Pathway , 2015, BioMed research international.

[39]  J. Ambrose,et al.  Pathophysiology of coronary artery disease leading to acute coronary syndromes , 2015, F1000prime reports.

[40]  Q. Tang,et al.  Icariin attenuates angiotensin II-induced hypertrophy and apoptosis in H9c2 cardiomyocytes by inhibiting reactive oxygen species-dependent JNK and p38 pathways , 2014, Experimental and therapeutic medicine.

[41]  Z. Yuan,et al.  Icariin Attenuates the Enhanced Prothrombotic State in Atherosclerotic Rabbits Independently of Its Lipid-Lowering Effects , 2013, Planta Medica.

[42]  M. Mezei,et al.  Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.

[43]  G. Wang,et al.  Divergent Tumor Necrosis Factor Receptor-Related Remodeling Responses in Heart Failure: Role of Nuclear Factor-&kgr;B and Inflammatory Activation , 2009, Circulation.

[44]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[45]  Zai-Qun Liu,et al.  Protective effect of icariin on DNA against radical‐induced oxidative damage , 2007, The Journal of pharmacy and pharmacology.

[46]  Zhao-quan Huang,et al.  Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. , 2007, Vascular pharmacology.

[47]  Y. Lou,et al.  Determination of rat urinary metabolites of icariin in vivo and estrogenic activities of its metabolites on MCF-7 cells. , 2005, Die Pharmazie.

[48]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[49]  L. Ye,et al.  [Advances in study on pharmacological effects of Epimedium]. , 2001, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.